Project Grant R01CA297077
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$730K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine supports research aimed at understanding and disrupting the adeno-to-squamous transition, a mechanism by which non-small cell lung cancer can adapt and become resistant to targeted therapies like KRAS inhibitors. The $703,410 award, effective January 16, 2025 through December 31, 2029, will fund a comprehensive research program to identify specific...
The National Cancer Institute (NCI) awarded a $730,398 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The grant supports a 5-year research project investigating the relationship between inflammatory signaling in the leptomeninges (the membranes surrounding the brain and spinal cord) and the growth of leptomeningeal metastases, which are a lethal complication of cancer. The project leverages the institute's collection of...
The National Cancer Institute (NCI) awarded a $1,592,358 Project Grant (CFDA 93.396 Cancer Biology Research) to The Leland Stanford Junior University (Stanford University) to conduct research on modulating cysteine metabolism to induce cell death in small cell lung cancer (SCLC). The project aims to determine how cysteine deprivation triggers cell state-specific lethal mechanisms in SCLC cells, focusing on the role of the GCN2/ATF4 amino acid sensing pathway, polyunsaturated phospholipid...
This Project Grant award of $730,407 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate how inhibiting the ULK1 protein kinase, which controls autophagy, impacts both tumor cell and immune cell metabolism in lung cancer. The award aims to: 1) Establish the metabolic effects of ULK1 inhibition on KRAS-driven lung tumors in vivo, 2) Dissect the impact of ULK1 inhibition on CD8+ T cell metabolism and function, and 3)...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The purpose of this 5-year grant is to develop multimodal predictive models that integrate real-world data from circulating tumor DNA (ctDNA) sequencing, radiomics, tumor registries, and tissue genomics to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The...
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $689,914 Project Grant under the Cancer Treatment Research (CFDA 93.395) federal grant program to the Icahn School of Medicine at Mount Sinai. The objective of this 5-year research project is to delineate the mechanisms by which concurrent STK11 and KEAP1 gene mutations in non-small cell lung cancer (NSCLC) promote ferroptosis evasion and therapy resistance, and to establish ferroptosis as a...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms driving acquired cross-resistance in small cell lung cancer (SCLC). The $642,429 award to the University of Texas Southwestern Medical Center, effective January 1, 2025 through December 31, 2029, aims to investigate how extrachromosomal MYC amplifications contribute to broad chemotherapy resistance in SCLC patient-derived...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $230,010 to the University of Chicago to conduct research aimed at unraveling the mechanisms driving metastasis in small cell lung cancer (SCLC). The research strategy integrates human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to investigate the cellular and molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to investigate SMARCA2 as a therapeutic target for SMARCA4-deficient lung cancers. The $557,418 award, effective March 17, 2025 through February 28, 2030, will fund the development of genetically engineered mouse models to evaluate the effects of SMARCA2 degradation on tumor progression and mechanisms of response and resistance in SMARCA4-deficient lung adenocarcinomas. The...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Treatment Research" (CFDA 93.395), awarded a Project Grant of $402,600.00 to the Sloan-Kettering Institute for Cancer Research. The grant supports the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP complex for the treatment of acute myeloid leukemia (AML). The key objectives are to (1) evaluate the efficacy and safety of U5 snRNP200-targeted CAR T cells,...